AKURACY®

13
N-Ammonia
total solution
for cardiac PET
imaging
INTRODUCING AKURACY®
The total solution for
accurate cardiac diagnostics

Imagine you could give your patients a faster, more precise diagnosis
of their cardiac condition. Suppose you could use advanced
PET imaging to identify coronary artery disease with greater
accuracy and capitalize on 13
N-NH3-based PET imaging to make the
whole diagnostic process more patient-friendly. Think of all the
advantages... rapid throughput, lower radiation burden and a wealth
of clinical information.

IBA makes this possible. We draw on our vast experience developing and integrating
versatile cyclotrons into total solutions like Akuracy® to enrich every single step of the
cardiac PET diagnostic process: from setting up the cyclotron at your imaging facility
and producing the 13N-Ammonia (13N-NH3) tracer to training your people in typical
daily use and maintenance.

Find out why our total solution is your best (cardio)logical choice.
PATIENT-
CENTERED CARE

FULL INDEPENDENCE
AKURACY® enables cardiac imaging centers to achieve full independence from external
radiotracer suppliers by providing on-demand, in-house production capabilities.

PATIENT-FRIENDLY
The diagnostic process is a better experience for patients than the conventional imaging
process, as the patient workflow is faster and much less radiation exposure (max. 2 mSv).

EASE OF USE
The entire process is controlled by high-level software with an intuitive interface that
can be operated by qualified personnel. From tracer production to dose availability, on
demand and tailored to your schedule.

LOW OPEX
Fully automated production results in higher daily patient throughput, reducing your
operating expenses and saving your time.

Ammonia dose

Sterile
Cyclotron filtration
1 click button
16
O(p,α)13N at 9.2 MeV
Up to 40 mCi/10 min
QC
Ammonia

Dose can be delivered each 10 min,

as irradiation and post process
can be parallelized
(transfer time to injection not included) Purification
“
AKURACY®
IS POWERED
BY IBA

IBA (Ion Beam Applications) draws on its experience in oncology

diagnostics acquired over decades to develop integrated
radiopharmacy solutions, like Akuracy®, that combine equipment
and services to improve cardiac diagnostics and patient care.
FOR 40 YEARS GLOBAL
LEADER IN RADIOPHARMA SOLUTIONS

IBA is the world-leading provider of radiopharmaceutical production integrated solu-

tions with long-standing expertise in Nuclear Medicine. IBA has a rich history as an
innovator developing state-of-the-art technologies to ensure healthcare professionals
always deliver the highest quality care to their patients.

IBA’s RadioPharma Solutions markets products and services that support the entire radiopharmaceutical
production process, from radiopharmacy setting-up until the dose readiness.
All solutions are designed to meet the unique needs of hospitals, distribution centers, and research
institutions worldwide.

EXPERTISE BENEFITING
FROM A LARGE INSTALLED BASE
Partnering with IBA gives you peace of mind that
you are always at the cutting edge of innovation,
capitalizing on our future developments.

IBA has a proven track record of customer satis-

faction, with more than 350 cyclotrons installed on
5 continents. IBA also provides continuous support
throughout the lifetime of your project, improving
your skills and applications, boosting your uptime,
and maximizing your return on investment with all
the latest innovations, services, and training.

In addition, the system is built to ensure that up-

grades can be implemented easily, so your system
always remains fully up-to-date.
PET IS THE FUTURE OF
NUCLEAR CARDIOLOGY

Cardiac PET (positron emission tomography) imaging is a fast-growing clinical

tool endorsed by well recognized clinical guidelines and has demonstrated its high
accuracy and precision. This powerful non-invasive imaging technique can assess
myocardial blood flow (MBF) throughout the coronary circulation system, epicardial
vessels and microvasculature, making it more effective and more efficient as a
functional imaging modality.
 Cardiac PET imaging offers an array of advantages that make it more
attractive than SPECT imaging for assessing coronary artery disease:

HIGHER RESOLUTION AND ADVANCED IMAGE

ACQUISITION/RECONSTRUCTION
PET provides better quality static and ECG gated images and
more importantly: dynamic quantitative data on myocardial blood
flow during peak stress and at rest; a unique feature of PET.

BETTER SENSITIVITY AND SPECIFICITY

The combination of data from static, ECG-gated and dynamic
images makes PET a more sensitive and specific functional
imaging modality for the detection of coronary artery disease,
reducing downstream costs.

GREATER VERSATILITY
Broad variety of tracers available (perfusion and metabolism)
makes it a more versatile modality.

LOWER RADIATION EXPOSURE

PET imaging uses radiotracers with shorter half-lives for myocardial
perfusion imaging, reducing patient radiation exposure.

WEALTH OF CLINICAL INFORMATION

MBF Quantitative PET (myocardial blood flow) generates greater
insight into coronary physiology and pathology.

“ CARDIAC PET
IMAGING LEADS
TO IMPROVED
DIAGNOSTIC
ACCURACY AND
PATIENT OUTCOMES.
13
N-AMMONIA
The fast track to accurate diagnosis

Cardiac PET imaging is known to provide better image quality than SPECT imaging, but the
choice of radiotracer is also important. Our choice: 13N-Ammonia.

ADVANTAGES

13
N-Ammonia is an effective diagnostic tool that improves patient management by
accurately detecting coronary artery disease (CAD) due to its short positron range,
high sensitivity, and high first-pass extraction and retention properties in the myocardium.
Increasingly preferred by leading cardiac imaging institutes, 13N-Ammonia is experiencing
rapid adoption for cardiac PET imaging, as it provides diagnostic studies of consistently
high-quality, regardless of patient size or gender.
ADVANTAGES

IMPROVED PROGNOSTIC AND DIAGNOSTIC ACCURACY

QUANTITATIVE ASSESSMENT OF MBF

BETTER QUALITY IMAGES

LOWER RADIATION EXPOSURE

RANGE OF STRESS PROTOCOLS

AKURACY® SOLUTION
13
N-Ammonia production on-demand

The IBA Akuracy® solution is an innovative user-friendly system designed for the
automated production of 13
N-NH3. The system is a single button solution that any
qualified technologist can easily operate from the PET control room, making it a
convenient and efficient tool for producing 13
N-NH3 on demand.

ADVANTAGES

Akuracy® is designed to produce a ready-to-use 13N-Ammonia dose about every 10 minutes, significantly reducing
patient waiting times and improving the workflow efficiency. The system includes in-line advanced quality control
features, ensuring all radiopharmaceuticals comply with the pharmacopeial quality standards.

WORKING FOR YOU

Our team of radiopharmaceutical experts creates custom systems for the GMP production of 13N-Ammonia.
We draw on decades worth of experience in the design and integration of radiopharmaceutical production
facilities to devise solutions tailored to the individual needs of each customer. The integrated solution includes
all necessary hardware and software for the seamless production, purification/dispensing, and quality control
of 13N-NH3.

SOLUTION FIGURES OF MERIT

Patient throughput Up to 1 dose every +/- 10 min

Production cycle Dose-on-demand

Production workflow Fully automated

Staff requirement Minimum (high-level software supervision)

Process sterilization Aseptic process

Hotcell pharmaceutical gradee A (isolator)

Fully automated: sampling, measurements,

QC workflow
and reporting

Quality control Compliant with the EU pharmacopoeia specifications

Dispensing output Shielded syringe

Dispensing exit atmosphere Unclassified area

 GMP layout, detailed room Purification module &
data sheets & associated Automated dispensing hot cell
set of drawings

Compact & fully N-NH3 dose on-demand

13

automated QC module next to your camera

Activation-free
self-shielding

Your preferred
PET/CT camera

Centralized supervision
Cyclone® KEY & One-click button
13
N Nirta® target production control
Start-up training,
maintenance & warranty
for IBA equipment

“ THE
ENSURES
IBA TEAM OF EXPERTS
EFFICIENT AND RELIABLE
13
N-AMMONIA PRODUCTION.

CYCLOTRON SPECIFICATIONS

Energy 9.2 MeV

Extracted beam current 30 µA

Route of production 16
O(p,α)13N

Beam-on power consumption < 37 kW

Stand-by power consumption < 3 kW

Activation-free high-density polyethylene

Self-shielding technology
(HDPE) and high-density concrete

Magnet technology Normal conducting

Pumping technology 1x primary pump + 1x turbomolecular pump

Target technology Helium cooling free

Cyclotron weight 7.5 Tons

Self-Shielding weight 40 Tons

Cyclotron overall dimensions [m] 1.5 x 1.4 x 1.4 ( l x w x h)

Internal room dimensions with self-shielding [m] 6.1 x 4.3 x 2.7 ( l x w x h)

Radiopharmacy surface 80m² / 861 sq ft

ABOUT IBA (ION BEAM APPLICATIONS S.A)

IBA is a cancer diagnostics and treatment company and

the worldwide technology leader in the field of proton
­therapy. The company’s expertise lies in the development
of next-generation proton therapy technologies and
radiopharmaceuticals that provide oncology care providers
with premium quality services and equipment, including IBA’s
leading fully integrated IntegraLab® system.

ABOUT IBA RADIOPHARMA SOLUTIONS

Based on long-standing expertise, IBA RadioPharma Solutions

provides total solutions, from project design to facility operation,
to support in-house radioisotope production at hospitals and
radiopharmaceutical distribution centers. As well as high-quality
technology production equipment, IBA has in-depth experience
of setting up GMP radiopharmaceuticals production centers.

CONTACT US:
Chemin du Cyclotron, 3 | 1348 Louvain-la-Neuve, Belgium
Tel.: + 32 10 201 275 | Fax: + 32 10 47 59 58 |
[email protected]

www.iba-radiopharmasolutions.com/akuracy

IBA |AKURACY brochure - May 2023 - MID 116512/A © IBA SA | All rights reserved
While all care has been taken to ensure that the information contained in this publication
is correct, no responsibility can be accepted for any inaccuracy and we reserve the right
to modify this information. Technical specifications are based on standard operating
conditions and may be subject to variations.